Aspira Womens Health's revenue for the
three
months ended in Dec. 2023 was €1.95 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €8.49 Mil.
Aspira Womens Health's Revenue per Share for the
three
months ended in Dec. 2023 was €0.19.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.93.
Warning Sign:
Aspira Womens Health Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Aspira Womens Health was -5.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Aspira Womens Health's highest 3-Year average Revenue per Share Growth Rate was 130.60% per year. The lowest was -91.30% per year. And the median was 1.20% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's Revenue
For the Diagnostics & Research subindustry, Aspira Womens Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Revenue distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Revenue falls into.
Aspira Womens Health Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (FRA:CUL) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Aspira Womens Health Revenue Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (FRA:CUL) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:CUL has been successfully added to your 